作者
Kenichi Nakamura, Ken Kato, Hiroyasu Igaki, Yoshinori Ito, Junki Mizusawa, Nobutoshi Ando, Harushi Udagawa, Yasuhiro Tsubosa, Hiroyuki Daiko, Shuichi Hironaka, Haruhiko Fukuda, Yuko Kitagawa, Japan Esophageal Oncology Group/Japan Clinical Oncology Group
发表日期
2013/7/1
期刊
Japanese journal of clinical oncology
卷号
43
期号
7
页码范围
752-755
出版商
Oxford University Press
简介
A three-arm Phase III trial was started in November 2012. Preoperative chemotherapy with cisplatin plus 5-fluorouracil is the current standard treatment for locally advanced esophageal cancer in Japan, while preoperative chemoradiotherapy with cisplatin plus 5-fluorouracil is the standard in Western countries. Preoperative chemotherapy with docetaxel, cisplatin plus 5-fluorouracil is another promising regimen. The purpose of this study is to confirm the superiority of docetaxel, cisplatin plus 5-fluorouracil over cisplatin plus 5-fluorouracil and the superiority of cisplatin plus 5-fluorouracil with chemoradiotherapy over cisplatin plus 5-fluorouracil as preoperative therapy for squamous cell carcinoma of esophagus. A total of 501 patients will be accrued from 41 Japanese institutions within 6.25 years. The primary endpoint is overall survival and the secondary endpoints include progression-free survival, %R0 …
学术搜索中的文章
K Nakamura, K Kato, H Igaki, Y Ito, J Mizusawa… - Japanese journal of clinical oncology, 2013